Blockade of Programmed Death Receptor Pathway as a Therapeutic Strategy in Osteosarcoma

Project: Research project

Project Details

Description

Blockade of Programmed Death Receptor Pathway as a Therapeutic Strategy in Osteosarcoma Osteosarcoma Project Conventional approaches for treatment of metastatic osteosarcoma remain dismal with a 5-year survival rate for children diagnosed with this disease of less than 20%. The goal of this proposal is to test whether blockade of programmed death receptor (PD-1) signals can enhance T cell function during metastatic osteosarcoma, and thereby improve immune control of tumors during chemotherapy. We have previously shown that human metastatic osteosarcoma, but not primary tumors, express the ligand for the PD-1 (PD-L1), and that metastases infiltrating T cells express PD-1. Thus, we believe that this pathway limits the ability of tumor infiltrating T cells to mediate tumor rejection during osteosarcoma metastasis, as it does in many other tumor settings.
StatusFinished
Effective start/end date7/1/1412/1/15

Funding

  • INDUSTRY: Domestic Company: $120,000.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.